[go: up one dir, main page]

TW200801012A - Phosphoinositide 3-kinase inhibitor compounds and methods of use - Google Patents

Phosphoinositide 3-kinase inhibitor compounds and methods of use

Info

Publication number
TW200801012A
TW200801012A TW096114440A TW96114440A TW200801012A TW 200801012 A TW200801012 A TW 200801012A TW 096114440 A TW096114440 A TW 096114440A TW 96114440 A TW96114440 A TW 96114440A TW 200801012 A TW200801012 A TW 200801012A
Authority
TW
Taiwan
Prior art keywords
methods
phosphoinositide
kinase inhibitor
compounds
inhibitor compounds
Prior art date
Application number
TW096114440A
Other languages
English (en)
Inventor
Georgette Castanedo
Richard Goldsmith
Janet Gunzner
Tim Heffron
Kimberly Malesky
Simon Mathieu
Alan Olivero
Daniel P Sutherlin
Vickie Tsui
Shumei Wang
Christian Wiesmann
Bing-Yan Zhu
Jennafer Dotson
Adrian FOLKES
Stephen Shuttleworth
Sally Oxenford
Tim Hancox
Tracy Bayliss
Original Assignee
Piramed Ltd
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38561741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200801012(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Piramed Ltd, Genentech Inc filed Critical Piramed Ltd
Publication of TW200801012A publication Critical patent/TW200801012A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Surgery (AREA)
TW096114440A 2006-04-26 2007-04-24 Phosphoinositide 3-kinase inhibitor compounds and methods of use TW200801012A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79504706P 2006-04-26 2006-04-26

Publications (1)

Publication Number Publication Date
TW200801012A true TW200801012A (en) 2008-01-01

Family

ID=38561741

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096114440A TW200801012A (en) 2006-04-26 2007-04-24 Phosphoinositide 3-kinase inhibitor compounds and methods of use

Country Status (17)

Country Link
US (2) US7846929B2 (zh)
EP (1) EP2046799B1 (zh)
JP (1) JP5291616B2 (zh)
KR (1) KR101402474B1 (zh)
CN (1) CN101511840A (zh)
AR (1) AR060632A1 (zh)
AU (1) AU2007243466B2 (zh)
BR (1) BRPI0710908A2 (zh)
CA (1) CA2650295C (zh)
CL (1) CL2007001166A1 (zh)
IL (1) IL194761A0 (zh)
MX (1) MX2008013583A (zh)
NO (1) NO20084927L (zh)
RU (1) RU2437888C2 (zh)
TW (1) TW200801012A (zh)
WO (1) WO2007127183A1 (zh)
ZA (1) ZA200810023B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499592B (zh) * 2009-09-09 2015-09-11 Avila Therapeutics Inc Ｐｉ３激酶抑制劑及其用途

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1577816A3 (en) * 1996-09-04 2006-08-02 Intertrust Technologies Corp. Trusted infrastructure support systems, methods and techniques for secure electronic commerce and rights management
CL2007001166A1 (es) 2006-04-26 2008-01-25 Piramed Ltd Compuestos derivados de pirimidina condensada, inhibidores de pi3-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicion farmaceutica
PL2041139T3 (pl) * 2006-04-26 2012-05-31 Hoffmann La Roche Związki farmaceutyczne
BRPI0717907A2 (pt) * 2006-12-07 2013-11-05 Genentech Inc "composto, composição farmacêutica, métodos para tratar um câncer, para inbir ou modular a atividade da lipídeo quinase, processo para a produçãoo de uma composição farmacêutica, uso de um composto e kit"
AR064155A1 (es) 2006-12-07 2009-03-18 Piramed Ltd Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso
KR101472607B1 (ko) * 2007-02-20 2014-12-15 노파르티스 아게 지질 키나제 및 ｍＴＯＲ의 이중 억제제로서의 이미다조퀴놀린
EP2158207B1 (en) * 2007-06-12 2011-05-25 F. Hoffmann-La Roche AG Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
CA2699202C (en) * 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
EP2207781B1 (en) * 2007-09-24 2012-11-28 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
CN101835779B (zh) * 2007-10-26 2014-01-29 霍夫曼-拉罗奇有限公司 作为pi3激酶抑制剂的嘌呤衍生物
CN102088995B (zh) 2008-05-14 2016-01-20 维多利亚农业服务控股公司 血管生成素和血管生成素激动剂用于治疗疾病和障碍的用途
WO2009146406A1 (en) * 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
AU2009276339B2 (en) * 2008-07-31 2012-06-07 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
JP2012505836A (ja) 2008-10-17 2012-03-08 アカール ファーマ ピーティーワイ リミテッド Ｓ１ｐ受容体モジュレーターおよびそれらの使用
WO2010042998A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
US8586582B2 (en) 2008-11-11 2013-11-19 Xcovery Holding Company, Llc PI3K/mTOR kinase inhibitors
JP5689069B2 (ja) * 2008-11-20 2015-03-25 ジェネンテック， インコーポレイテッド ピラゾロピリジンｐｉ３ｋ阻害剤化合物及び使用方法
PE20141317A1 (es) * 2009-01-08 2014-09-26 Merck Patent Gmbh Nuevas formas polimorficas de sal de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo y sus procesos de preparacion
HRP20150947T1 (hr) * 2009-01-08 2015-10-09 Curis, Inc. Inhibitori fosfoinositid 3-kinaze sa skupinom koja veže cink
CA2753285A1 (en) 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
JP5647998B2 (ja) * 2009-03-13 2015-01-07 カトリーケ ユニバーシテイト ルーヴェン、ケー．ユー． ルーヴェン アール アンド ディー 免疫抑制剤としてのチアゾロピリミジン調節因子
ES2527046T3 (es) 2009-03-24 2015-01-19 Sumitomo Chemical Company, Limited Método para la preparación de un compuesto de éster del ácido borónico
US8461158B2 (en) 2009-03-27 2013-06-11 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
SG182247A1 (en) * 2009-05-27 2012-08-30 Hoffmann La Roche Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
SG175708A1 (en) * 2009-05-27 2011-12-29 Genentech Inc Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
SG176959A1 (en) * 2009-06-24 2012-01-30 Genentech Inc Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
EP2532659A1 (en) 2009-07-07 2012-12-12 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
AU2010279384A1 (en) * 2009-08-05 2012-03-01 Wake Forest University Compositions and methods for inducing apoptosis in prostate cancer cells
PE20170003A1 (es) 2009-08-17 2017-03-15 Intellikine Llc Compuestos heterociclicos y usos de los mismos
MX2012002059A (es) 2009-08-20 2012-04-19 Karus Therapeutics Ltd Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa.
EP2475367A1 (en) * 2009-09-10 2012-07-18 Centre National De La Recherche Scientifique NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
SG10201407781SA (en) 2009-09-28 2015-01-29 Hoffmann La Roche Benzoxepin PI3K Inhibitor Compounds And Methods Of Use
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
RS56432B1 (sr) 2009-11-05 2018-01-31 Rhizen Pharmaceuticals S A Novi benzopiran modulatori kinaze
US8828990B2 (en) * 2009-11-12 2014-09-09 Genentech, Inc. N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use
CN102711766B (zh) * 2009-11-12 2014-06-04 霍夫曼-拉罗奇有限公司 N-9-取代的嘌呤化合物、组合物和使用方法
UY33199A (es) * 2010-01-26 2011-08-31 Boehringer Ingelheim Int 5-alquinil-pirimidinas.
EP2539337A1 (en) 2010-02-22 2013-01-02 F. Hoffmann-La Roche AG Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
UY33304A (es) * 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
CA2802808A1 (en) 2010-07-14 2012-01-19 F. Hoffmann-La Roche Ag Purine compounds selective for pi3k p110 delta, and methods of use
AU2011343712B2 (en) * 2010-12-16 2015-09-17 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
US20140206678A1 (en) * 2011-01-27 2014-07-24 Kadmon Corporation, Llc Inhibitors of mtor kinase as anti -viral agent
KR20130116358A (ko) 2011-02-09 2013-10-23 에프. 호프만-라 로슈 아게 Pi3 키나아제 억제제로서 헤테로사이클릭 화합물
WO2012126901A1 (en) 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
BR112013024907A2 (pt) 2011-03-28 2016-12-20 Mei Pharma Inc composto, composição farmacêutica, método para o tratamento, prevenção ou atenuação de um ou mais sintomas de um distúrbio, doença ou condição mediada por pi3k em um sujeito, método para modular a atividade enzimática de pi3k
LT3111938T (lt) 2011-04-01 2019-06-25 Curis, Inc. Fosfoinozitido 3-kinazės inhibitorius su cinko rišamąja dalimi
MX365160B (es) 2011-05-04 2019-05-24 Rhizen Pharmaceuticals Sa Compuestos novedosos como moduladores de proteína cinasas.
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
KR101255939B1 (ko) * 2011-05-31 2013-04-23 동화약품주식회사 4-(1ｈ-인다졸-6-일아미노)-ｎ-아이소프로필-2-(메틸티오)피리미딘-5-카르복스아미드 화합물 또는 이의 약학적으로 허용가능한 염을 포함하는 당뇨병 예방 또는 치료용 조성물
CA2849331A1 (en) * 2011-10-13 2013-04-18 Genentech, Inc. Treatment of pharmacological-induced hypochlorhydria
JP6126615B2 (ja) * 2011-11-11 2017-05-10 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
CN102643272B (zh) * 2011-12-30 2015-03-11 沈阳药科大学 新的噻吩并[3,2-d]嘧啶类化合物
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
FR2988722B1 (fr) 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
CN103467482B (zh) 2012-04-10 2017-05-10 上海璎黎药业有限公司 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
US9790233B2 (en) 2012-04-16 2017-10-17 Case Western Reserve University Compositions and methods of modulating 15-PGDH activity
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
WO2013168671A1 (ja) * 2012-05-07 2013-11-14 キッセイ薬品工業株式会社 ピラゾール誘導体及びその医薬用途
AU2013204740C1 (en) 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
CN104350144B (zh) 2012-05-23 2017-08-04 弗·哈夫曼-拉罗切有限公司 获得和使用内胚层和肝细胞的组合物和方法
MX2014014831A (es) 2012-06-08 2015-02-12 Hoffmann La Roche Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
SG11201408821SA (en) 2012-07-04 2015-01-29 Rhizen Pharmaceuticals Sa Selective pi3k delta inhibitors
WO2014033196A1 (en) * 2012-08-30 2014-03-06 F. Hoffmann-La Roche Ag Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
EP2917202B1 (en) 2012-11-07 2018-05-02 Karus Therapeutics Limited Novel histone deacetylase inhibitors and their use in therapy
JP6496301B2 (ja) * 2013-04-12 2019-04-03 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー Ｒａｓ／ｒａｆ／ｍｅｋ／ｅｒｋ経路およびｐｉ３ｋ／ａｋｔ／ｐｔｅｎ／ｍｔｏｒ経路の二重阻害剤としてのキナゾリンおよびアザキナゾリン
CA2911856A1 (en) 2013-05-10 2014-11-13 Karus Therapeutics Ltd Tri-substituted amino hydroxamate compounds and pharmaceutical compositions thereof for use as histone deacetylase inhibitors
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2015043398A1 (zh) 2013-09-30 2015-04-02 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
US9789116B2 (en) 2013-10-15 2017-10-17 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CN104557872B (zh) 2013-10-16 2017-05-24 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
SG11201606367YA (en) 2014-02-06 2016-09-29 Abbvie Inc 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
HK1250636A1 (zh) 2015-03-08 2019-01-11 卡斯西部储备大学 用於治疗纤维症的短链脱氢酶活性的抑制剂
WO2016154075A1 (en) * 2015-03-20 2016-09-29 Vertex Pharmaceuticals Incorporated Bicyclic heteroaryl compounds useful as inhibitors of the par-2 signaling pathway
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
PT3277682T (pt) * 2015-03-30 2019-07-09 Daiichi Sankyo Co Ltd Derivados de 6-morfolinil-2-pirazolil-9h-purina e utilização dos mesmos como inibidores de pi3k
US20180118756A1 (en) * 2015-04-14 2018-05-03 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CA2981159A1 (en) 2015-06-29 2017-01-05 F. Hoffmann-La Roche Ag Methods of treatment with taselisib
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
CN107098846B (zh) * 2016-02-26 2020-10-09 中国医学科学院药物研究所 N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途
WO2017197151A1 (en) 2016-05-11 2017-11-16 Emory University Phosphotidylinositol 3-kinase inhibitors
RU2743170C2 (ru) 2016-06-01 2021-02-15 Байер Энимал Хелс Гмбх Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных
WO2018057588A1 (en) * 2016-09-21 2018-03-29 Vertex Pharmaceuticals Incorporated Furo[3,2-b]pyridine compounds useful as inhibitors of the par-2 signaling pathway
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
NZ796735A (en) 2017-02-06 2025-12-19 Univ Case Western Reserve Compositions and methods of modulating short-chain dehydrogenase activity
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
KR102736865B1 (ko) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
KR20200041358A (ko) 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법
CN109796465B (zh) * 2017-11-16 2020-07-14 华中科技大学同济医学院附属协和医院 靶向pet显像化合物、包含该化合物的显象剂及其制备方法和用途
CA3102279A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
US11234986B2 (en) 2018-09-11 2022-02-01 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
JP7598642B2 (ja) * 2018-10-12 2024-12-12 ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ ネブラスカ ホスホジエステラーゼ阻害剤
CN120463720A (zh) 2018-11-21 2025-08-12 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
IL294504A (en) 2020-01-13 2022-09-01 Verge Analytics Inc Converted pyrazolo-pyrimidines and their uses
EP4161519A4 (en) * 2020-06-03 2024-07-17 Yumanity Therapeutics, Inc. PURINES AND METHODS OF USE
KR20230106648A (ko) * 2020-11-10 2023-07-13 포그혼 쎄라퓨틱스 인크. 화합물 및 그의 용도
US20240182465A1 (en) * 2021-03-03 2024-06-06 Genfleet Therapeutics (Shanghai) Inc. Fused ring substituted six-membered heterocyclic compound, preparation method therefor and use thereof
WO2022266251A1 (en) * 2021-06-16 2022-12-22 The Board Of Trustees Of The Leland Stanford Junior University Compositions for treatment of psoriasis
WO2022268025A1 (zh) * 2021-06-22 2022-12-29 成都苑东生物制药股份有限公司 Atr抑制剂及其用途
CN118019744A (zh) * 2021-09-30 2024-05-10 韩美药品株式会社 PIKfyve激酶抑制剂
CN115991716B (zh) * 2021-10-19 2025-10-17 中国药科大学 嘧啶并环类化合物及其衍生物、制备方法、药物组合物和应用
CN118488947A (zh) * 2022-01-04 2024-08-13 劲方医药科技(上海)有限公司 稠环取代的六元杂环化合物及其制法和用途
CN114539293B (zh) * 2022-02-24 2023-09-22 广东晨康生物科技有限公司 一种噻吩并嘧啶类化合物或其药学上可接受的盐及其制备方法和应用
KR20250024923A (ko) 2022-05-11 2025-02-20 포그혼 쎄라퓨틱스 인크. 화합물 및 그의 용도
CN117164590A (zh) * 2022-05-25 2023-12-05 沈阳药科大学 稠合嘧啶类衍生物及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
RO62428A (fr) 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
CH592668A5 (zh) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
ZA782648B (en) 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
KR100774855B1 (ko) * 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
EP1353693B1 (en) * 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
AU2002349912A1 (en) * 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
AU2002357667A1 (en) * 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
WO2004017950A2 (en) * 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
CL2007001166A1 (es) 2006-04-26 2008-01-25 Piramed Ltd Compuestos derivados de pirimidina condensada, inhibidores de pi3-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicion farmaceutica
US20110230476A1 (en) * 2009-09-09 2011-09-22 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499592B (zh) * 2009-09-09 2015-09-11 Avila Therapeutics Inc Ｐｉ３激酶抑制劑及其用途

Also Published As

Publication number Publication date
AR060632A1 (es) 2008-07-02
MX2008013583A (es) 2008-10-31
US20080039459A1 (en) 2008-02-14
KR20090024682A (ko) 2009-03-09
EP2046799B1 (en) 2017-07-19
RU2437888C2 (ru) 2011-12-27
EP2046799A1 (en) 2009-04-15
CL2007001166A1 (es) 2008-01-25
CN101511840A (zh) 2009-08-19
AU2007243466A1 (en) 2007-11-08
KR101402474B1 (ko) 2014-06-19
IL194761A0 (en) 2009-08-03
JP5291616B2 (ja) 2013-09-18
AU2007243466B2 (en) 2012-01-19
WO2007127183A1 (en) 2007-11-08
BRPI0710908A2 (pt) 2012-06-26
CA2650295C (en) 2015-12-29
NO20084927L (no) 2009-01-23
US7846929B2 (en) 2010-12-07
US8450315B2 (en) 2013-05-28
JP2009535335A (ja) 2009-10-01
ZA200810023B (en) 2009-08-26
CA2650295A1 (en) 2007-11-08
US20110105464A1 (en) 2011-05-05
RU2008145662A (ru) 2010-06-10

Similar Documents

Publication Publication Date Title
TW200801012A (en) Phosphoinositide 3-kinase inhibitor compounds and methods of use
MX2010002543A (es) Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
WO2007127175A3 (en) Pharmaceutical compounds
MX2010010659A (es) Compuestos de benzopirano y benzoxepina, inhibidores de fosfoinoinositida 3-cinasas y metodos para utilizarlos.
SG10201407781SA (en) Benzoxepin PI3K Inhibitor Compounds And Methods Of Use
MX2011009167A (es) Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas.
MX2009005950A (es) Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso.
MX2009005925A (es) Compuestos inhibidores de fosfoinositida 3-quinasa y los metodos de uso.
TW200800996A (en) Heterobicyclic pyrazole compounds and methods of use
AU2009312464A8 (en) Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes
PH12013501779A1 (en) Pyrrolopyridines as kinase inhibitors
MX2011012520A (es) Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos.
MX340013B (es) Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso.
SG178899A1 (en) Raf inhibitor compounds and methods of use thereof
WO2007146824A3 (en) Quinoline compounds and methods of use
WO2009111278A3 (en) Raf inhibitor compounds and methods of use thereof
WO2007027855A3 (en) Raf inhibitor compounds and methods of use thereof
SG178900A1 (en) Raf inhibitor compounds and methods of use thereof
MX2014014828A (es) Compuestos de 5-azaindazol y metodos de uso.
WO2006125101A3 (en) Raf inhibitor compounds and methods of use thereof
WO2008028141A3 (en) Raf inhibitor compounds and methods of use thereof
UA98946C2 (en) Phosphoinositide 3-kinase inhibitor compounds and methods of use
TH106829A (th) สารประกอบตัวยับยั้ง pi3k เบนโซไพแรน และ เบนโซซีพิน และวิธีการของการใช้
NZ620928A (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use